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Abstract
The Fc gamma receptors have been shown to play important
roles in the initiation and regulation of many immunological and
inflammatory processes and to amplify and refine the immune
response to an infection. We have investigated the hypothesis
that polymorphism within the FCGR genetic locus is associated
with giant cell arteritis (GCA). Biallelic polymorphisms in
FCGR2A, FCGR3A, FCGR3B and FCGR2B were examined
for association with biopsy-proven GCA (n = 85) and healthy
ethnically matched controls (n = 132) in a well-characterised
cohort from Lugo, Spain. Haplotype frequencies and linkage
disequilibrium (D') were estimated across the FCGR locus and
a model-free analysis performed to determine association with
GCA. There was a significant association between FCGR2A-
131RR homozygosity (odds ratio (OR) 2.10, 95% confidence
interval (CI) 1.12 to 3.77, P = 0.02, compared with all others)
and carriage of FCGR3A-158F (OR 3.09, 95% CI 1.10 to 8.64,
P = 0.03, compared with non-carriers) with susceptibility to
GCA. FCGR haplotypes were examined to refine the extent of
the association. The haplotype showing the strongest
association with GCA susceptibility was the FCGR2A-
FCGR3A 131R-158F haplotype (OR 2.84, P = 0.01 for
homozygotes compared with all others). There was evidence of
a multiplicative joint effect between homozygosity for FCGR2A-
131R and HLA-DRB1*04 positivity, consistent with both of
these two genetic factors contributing to the risk of disease. The
risk of GCA in HLA-DRB1*04 positive individuals homozygous
for the FCGR2A-131R allele is increased almost six-fold
compared with those with other FCGR2A genotypes who are
HLA-DRB1*04 negative. We have demonstrated that FCGR2A
may contribute to the 'susceptibility' of GCA in this Spanish
population. The increased association observed with a
FCGR2A-FCGR3A haplotype suggests the presence of
additional genetic polymorphisms in linkage disequilibrium with
this haplotype that may contribute to disease susceptibility.
These findings may ultimately provide new insights into disease
pathogenesis.
Introduction
Giant cell arteritis (GCA) is a common chronic granulomatous
vasculitis that is restricted to the over-50 population and thus
serves as a paradigm for ageing-related immunopathology.
Permanent ischaemic lesions, predominantly irreversible blind-
ness, occur in 15% of patients due to hyperplasia of the intimal
layer of involved arteries and non-thrombotic luminal occlu-
sion. Some patients present acutely with blindness, secondary
to anterior ischaemic optic neuropathy or central retinal artery
occlusion, whereas others present with a systemic inflamma-
tory syndrome [1]. High-dose steroids are conventionally used
to prevent these ischaemic complications, but in an elderly
population this leads to a high incidence of adverse events [2].
There is some evidence that GCA is an antigen-driven, autoim-
mune disease. One of the earliest changes within the vessel
wall is the accumulation of dendritic cells within the adventitia,
which are believed to initiate and maintain antigen-specific
adaptive immune responses, following an as yet unknown vas-
cular insult [3]. The familial clustering of GCA supports aPage 1 of 6
(page number not for citation purposes)
CI = confidence interval; FcγR = Fc gamma receptor; GCA = giant cell arteritis; NA = neutrophil antigen; OR = odds ratio.
Arthritis Research & Therapy    Vol 8 No 4    Morgan et al.genetic component, and there is a strong association with
HLA-DRB1*04 in many different populations [4]. Within
cohorts of biopsy-proven GCA, HLA-DRB1*04 is associated
with systemic signs and symptoms [5], visual manifestations
[6] and corticosteroid resistance [7]. Many other studies have
examined genetic variants in key components of immune and
inflammatory pathways known to be activated in this disease.
Associations with polymorphisms in genes encoding tumour
necrosis factor [8], interleukin-4 [9], intracellular adhesion mol-
ecule-1 [10], vascular endothelial growth factor [11,12] and
endothelial nitric oxide synthase have been reported in some
cohorts [13,14], although many are awaiting replication in a
second population. Variant alleles of mannose-binding lectin,
which result in low levels of mannose-binding lectin protein,
are also associated with GCA, perhaps through modulation of
phagocytic function [15].
There is some epidemiological evidence, such as clustering of
cases in space and time, that infection may act as a trigger for
both GCA and polymyalgia rheumatica [16]. Organisms pro-
posed include parvovirus B19 and Chlamydia pneumoniae,
but the evidence remains inconclusive [17]. Infections may
lead to vasculitis through various mechanisms: for example,
interactions between microbial ligands and endogenous mol-
ecules, impairment of pathogen clearance, molecular mimicry,
modification of self epitopes into 'neo-antigens', or failure to
down-regulate the alloimmune response [18]. The ageing
process itself leads to a functional decline in adaptive and
innate immune responses, known as immunosenescence, in
association with an increased susceptibility to infections,
malignancies and autoimmune/inflammatory disorders.
Although GCA-specific autoantibodies have not been
described, antibodies against a broad range of human autoan-
tigens have been observed in both types of GCA [19]. Anticar-
diolipin antibodies have been reported, particularly in biopsy-
positive GCA [20], and often disappear with steroid treatment
[21]. Furthermore, the pathogenicity of anti-endothelial anti-
bodies, which have been demonstrated in up to 50% of GCA
patients, remains to be elucidated, but such antibodies have
the potential to mediate Fc gamma receptor (FcγR) cross-link-
ing and trigger downstream effector functions [22].
The FcγRs, which bind IgG containing immune complexes/IgG
autoantibodies, have been shown to play important roles in the
initiation and regulation of many immunological and inflamma-
tory processes and to amplify and refine the immune response
to an infection. Activating FcγRs (FcγRI, FcγRIIa, FcγRIIIa,
FcγRIIIb) potentiate phagocytosis in response to IgG-contain-
ing immune complexes/opsonised micro-organisms and trig-
ger the oxidative burst, degranulation, maturation and release
of cytokines, including tumour necrosis factor-α [23-25].
FcγR-mediated endocytosis by antigen presenting cells, such
as dendritic cells, results in efficient MHC class I and II pres-
entation [26]. FcγRIIIa cross-linking additionally stimulates
antigen-dependent cellular cytotoxicity by natural killer cells
and macrophages. Conversely, FcγRIIb contains an inhibitory
motif in the cytoplasmic tail that abrogates cellular activation
and down-regulates the antibody response, thus acting as a
negative feedback mechanism [23-25]. Polymorphic variants
that increase the expression or affinity of these IgG receptors,
or enhance their ability to bind specific IgG isotypes, may,
therefore, play an important role in determining both the inflam-
mation mediated by IgG (auto)antibodies and IgG-containing
immune complexes and/or the susceptibility to specific infec-
tions that may be associated with triggering vascular/inflam-
matory disease.
We have examined the hypothesis that the FCGR genetic
locus is associated with susceptibility to GCA in a previously
well-characterised GCA cohort from north-western Spain.
Materials and methods
Giant cell arteritis patients and controls
This was an allelic association study where FCGR2A,
FCGR3A, FCGR3B and FCGR2B alleles and pairwise haplo-
types were examined in a well-characterised GCA cohort from
Lugo, Spain [6,27]. Briefly, all patients and controls were of
local Spanish descent and originated from the area surround-
ing Lugo, Galicia, in north-western Spain. They comprised 217
individuals (132 healthy controls and 85 GCA patients). All
patients were recruited from Xeral-Calde Hospital (Lugo) and
all patients fulfilled the 1990 American College of Rheumatol-
ogy criteria for the classification of GCA and had a positive
temporal artery biopsy [28]. All controls were healthy volun-
teers, who could trace their ancestry in the region for at least
three generations. Ethical approval was obtained from the
respective Local Research Ethics Committees.
FCGR genotyping
Genotyping at the FCGR locus is complex in view of the high
level of structural homology between the three class II
(FCGR2A, FCGR2B and FCGR2C) and two class III
(FCGR3A and FCGR3B) receptors. Gene duplication at this
locus is believed to have occurred as a result of an unequal
crossover event [29] with subsequent divergence of biological
functions. The functional FCGR2A-131H/R, FCGR3A-158F/
V and FCGR3B-NA1/NA2 polymorphisms and 3' untranslated
region FCGR2B-1206G/A single nucleotide polymorphism
were genotyped using assays that have previously been vali-
dated in our laboratory [30,31]. FCGR2A genotyping was per-
formed by direct sequencing for >80% of samples. The FCGR
gene order from centromere to telomere at chromosome 1q23
is FCGR2A, FCGR3A, FCGR2C, FCGR3B, FCGR2B
[31,32].
Statistical analyses
Statistical analyses were performed using the Stata statistical
software (Stata Corporation 2005, Stata Statistical Software:
Release 9.0, College Station, Texas, USA) unless otherwise
stated. The power calculations for this study were based onPage 2 of 6
(page number not for citation purposes)
Available online http://arthritis-research.com/content/8/4/R109the FCGR allele frequencies observed in the UK population
[31]. A cohort of 85 GCA cases and 130 controls provides
80% power to detect an odds ratio (OR) of 2.5 or 2.9 for a
dominant and recessive mode of inheritance, respectively,
assuming an allele frequency of 0.35 (5% significance level);
for an allele frequency of 0.5 the corresponding ORs are 3.2
and 2.5). Hardy-Weinberg equilibrium was investigated in
each control population using an exact test. Allele and geno-
type frequencies were compared using 2 × 2 and 3 × 2 con-
tingency tables, respectively. Two-sided P values below 0.05
were considered statistically significant throughout.
ORs and their 95% confidence intervals (CI) were calculated
to quantify the magnitude of all significant associations, as an
approximation of the relative risk. Haplotype frequencies were
estimated pairwise across the FCGR locus using the Estimat-
ing Haplotypes PLUS (EHPLUS) program [33], which also
calculates the empirical significance (P value) of overall link-
age disequilibrium. The standardised disequilibrium coeffi-
cient (D') was calculated for each pair of FCGRs, utilizing the
gene order derived from our electronic contig. The heteroge-
neity test within the Permutation and Model-free analysis pro-
gram was used to test for association with disease. A
permutation procedure implemented in this program enabled
1,000 permutations to be performed [33].
Association of FCGR haplotypes with GCA was investigated
further using the haplotype trend regression approach pro-
posed by Zaykin and colleagues [34] for dealing with uncer-
tain phase. In this method, logistic regression can be used to
relate disease status to an individual's haplotypes; where
these are not known with certainty all haplotypes consistent
with the genotypes are included as predictors, weighted by
their probabilities (based on the estimated haplotype frequen-
cies). This approach estimates the effect on risk of each hap-
lotype assuming the effect of the two haplotypes is
independent. Stepwise regression analyses were also used to
investigate a possible interaction with HLA-DRB1*04 [35].
Results
Association of FCGR2A, FCGR3A, FCGR3B and FCGR2B 
with giant cell arteritis
There was no evidence of departure from Hardy-Weinberg
equilibrium in the control group for any genotyped polymor-
phism.
There was weak evidence of a difference in the distribution of
FCGR2A-131H/R alleles (P = 0.05) and genotypes (P =
0.06) between cases and controls (Table 1). The data sup-
ported a recessive model and individuals homozygous for the
FCGR2A-131R allele had an increased risk of GCA (OR 2.10,
95% CI 1.12 to 3.77, P = 0.02, compared with all others).
There was also a trend towards an increase in the FCGR3A-
158F/V allele (P = 0.06) and genotype (P = 0.08) frequencies
in GCA patients compared to controls (Table 1). The data
were consistent with a dominant model and carriage of the
FCGR3A-158F allele was associated with GCA (OR 3.09,
95% CI 1.10 to 8.64, P = 0.03). There were no significant dif-
ferences in FCGR3B or FCGR2B allele or genotype frequen-
cies between GCA subjects and controls.
Linkage disequilibrium at the FCGR genetic locus
Significant linkage disequilibrium was observed between
FCGR2A and FCGR3A (D' = 0.31, P = 0.01) and FCGR3A
and FCGR3B (D' = -0.64, P = 0.0001) in the control popula-
tion. The negative D' values indicate linkage disequilibrium
between the commonest allele of one gene and the least com-
mon allele of the second gene (Table 2).
Table 2
Pairwise linkage disequilibrium measures (D') calculated from 
the control group
D' measures for the control population
FCGR2A FCGR3A FCGR3B
FCGR3A -0.31
FCGR3B -0.07 -0.64
FCGR2B -0.03 0.05 -0.37
Values of 0.3 and higher highlighted in bold.
Table 1
Genotype frequencies (number and proportion) in subjects 
with giant cell arteritis compared to controls
Gene Genotype Control (n 
= 132)
GCA (n = 
85)
P value
FCGR2A-
131
RR 29 (0.23) 32 (0.39)
RH 63 (0.51) 33 (0.40) 0.06
HH 32 (0.26) 18 (0.22)
FCGR3A-
158
FF 47 (0.41) 40 (0.48)
FV 49 (0.43) 38 (0.46) 0.08
VV 19 (0.16) 5 (0.06)
FCGR3B-
NA
22 49 (0.45) 36 (0.44)
21 50 (0.46) 35 (0.43) 0.77
11 10 (0.09) 10 (0.12)
FCGR2B-
1206
GG 59 (0.49) 36 (0.44)
GA 47 (0.39) 34 (0.41) 0.77
AA 15 (0.12) 12 (0.15)
GCA, giant cell arteritis.Page 3 of 6
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The distributions of two-locus FCGR haplotypes were com-
pared between the GCA and control populations, with a differ-
ence approaching statistical significance for FCGR2A-
FCGR3A (Table 3). Compared with the control frequency of
36%, the FCGR2A-FCGR3A 131R-158F haplotype was
found at increased frequency in GCA patients (50%).
From the haplotype trend regression analysis of FCGR2A-
FCGR3A haplotypes, the 131R-158F haplotype was found to
have a significant effect on the risk of GCA (OR 1.72, 95% CI
1.02 to 2.89, P = 0.04), compared to the H-V haplotype as
baseline. These are maximum likelihood estimates of the effect
of each haplotype assuming a log-additive combined effect of
an individual's two haplotypes. Further analysis treating the
number of copies of this haplotype as a factor shows that the
effect of the haplotype is largely confined to those with two
copies (data not shown). FCGR2A-FCGR3A haplotypes
were analysed under a recessive model, where homozygosity
for this haplotype was observed in 12% healthy controls com-
pared with 27% GCA population giving an OR of 2.84, 95%
CI 1.33 to 6.06 (P = 0.01) when homozygotes were com-
pared with all others.
Contribution of FCGR2A genotype and HLA-DRB1*04 
alleles in giant cell arteritis susceptibility
There was evidence of a multiplicative joint effect between
homozygosity for FCGR2A-131R and HLA-DRB1*04 positiv-
ity, consistent with both of these two genetic factors contrib-
uting to the risk of disease (OR 2.23, 95% CI 1.09 to 4.58 and
OR 2.61, 95% CI 1.30 to 5.22, respectively, from a model
including both predictors). Thus, the risk of GCA in HLA-
DRB1*04 positive individuals homozygous for the FCGR2A-
131R allele is increased almost six-fold compared with those
with other FCGR2A genotypes who are HLA-DRB1*04 neg-
ative. There is no evidence of an interaction between these
two genetic loci (P = 0.19 from a likelihood ratio test).
Discussion
We have demonstrated a significant association between
FCGR2A-131RR (OR 2.1, P = 0.02) and FCGR3A-158F
(OR 3.09, P = 0.03) with susceptibility to GCA. Haplotype
analyses can be more informative in their ability to identify dis-
ease predisposing genes. They may also provide additional
evidence for the presence of unidentified polymorphic variants
that are in linkage disequilibrium with the haplotype and are
the true disease-susceptibility variants [36]. Accordingly,
homozygosity for the FCGR2A-FCGR3A 131R-158F haplo-
type was associated with an almost three-fold increased risk
of GCA (OR 2.84, P = 0.01).
The FcγRs play important roles in the initiation and propaga-
tion of many different immunological and inflammatory proc-
esses. The two alloforms (FCGR2A-131R and FCGR3A-
158F) contained within the GCA-susceptibility haplotype
encode low affinity variants (FcγRIIa-131R and FcγRIIIa-158F).
FcγRIIa is the major phagocytic FcγR in humans and has two
co-dominantly expressed alleles, 131H and 131R. The 131H
isoform is the only FcγR that can bind IgG2, an antibody sub-
class that is also a poor activator of the classical complement
pathway. FCGR2A-131H is, therefore, essential for handling
IgG2 immune complexes: individuals homozygous for the
Table 3
Estimated pairwise haplotype frequencies in giant cell arteritis compared with healthy controls
Genes Haplotype Control GCA P value
FCGR2A-FCGR3A 131R-158F 0.360 0.502
131R-158V 0.135 0.078 0.07
131H-158F 0.246 0.208
131H-158V 0.259 0.212
FCGR3A-FCGR3B 158F-NA2 0.347 0.444
158F-NA1 0.272 0.268 0.16
158V-NA2 0.339 0.225
158V-NA1 0.042 0.063
FCGR3B-FCGR2B NA2-1206G 0.426 0.343
NA2-1206A 0.255 0.317 0.30
NA1-1206G 0.255 0.311
NA1-1206A 0.064 0.029
Pairwise haplotypes produced from four biallelic markers (FCGR2A-131H/R, FCGR3A-158F/V, FCGR3B-NA2/1 and FCGR2B-1206G/A) 
denoted in the order they occur at the FCGR locus. Thus, 131R-158F indicates a haplotype containing FCGR2A-131R and FCGR3A-158F 
alleles. Empirical P values were obtained from a heterogeneity test statistic incorporated in the Permutation and Model-free analysis program after 
1,000 permutations.Page 4 of 6
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bility to various encapsulated bacterial infections, such as
Neisseria meningitides, Haemophilus influenzae and Strepto-
coccus pneumoniae [37-39]. FcγRIIIa is expressed on natural
killer cells, macrophages, γδ T-cells and a subset of mono-
cytes. Consequently, they may act as susceptibility factors for
GCA through a variety of mechanisms, such as an inability to
bind IgG2 haplotypes (FcγRIIa-131R) on a background of
impaired FcγR-mediated phagocytosis (FcγRIIa-131R and
FcγRIIIa-158F) and impaired antigen-dependent cellular cyto-
toxicity of IgG-opsonised cells (FcγRIIIa-158F). Alternatively,
FcγR polymorphisms may modulate endothelial leukocyte
ingress, dendritic cell endocytosis and antigen presentation
[26], or macrophage/natural killer cell effector functions to IgG
containing immune complexes, each of which could separately
influence the pathogenesis of GCA.
The same polymorphic variants have also been demonstrated
to be associated with susceptibility to a variety of autoimmune
diseases. For example, systemic lupus erythematosus is asso-
ciated with the same FCGRIIA-131R, FCGRIIIA-158F and
FCGRIIIB-NA2 alleles, whereas relapses in Wegener's gran-
ulomatosis are associated with FCGRIIA-131R and FCGRI-
IIA-158F alleles [40]. Flares in both systemic lupus
erythematosus and Wegener's may be triggered by infection,
particularly chronic nasal carriage of Staphylococcus aureus
in the latter, but the picture is also complicated by impaired
FcγR-mediated clearance of pathogenic autoantibodies and
immune complexes.
Conclusion
Genetic polymorphism within the FCGR genetic locus may
contribute to the development of GCA. The immunological
consequences of these subtle defects in the innate immune
system may be enhanced in the presence of immunosenes-
cence, and the increased susceptibility to infection may poten-
tially allow triggering of the inflammatory process in GCA.
Additional studies from other ethnic groups will be required to
confirm these genetic associations.
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